What happened with CPHI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
China Pharma Holdings operates through its wholly owned Chinese subsidiary Helpson, which develops, manufactures and markets mainly prescription medicines. Most of its medicines are branded generics whose patents have expired. Products for viral infections, other infections and respiratory conditions bring in the largest share of revenue, followed by medicines for central nervous system, cerebral and cardiovascular conditions.
Pharmaceutical distributors in China buy the products and supply hospitals and retail pharmacies. These distributors provide all revenue, but their purchase agreements generally cover individual orders rather than ongoing commitments. Hospitals are the main end customers, so sales depend on hospital purchasing and doctors’ willingness to prescribe. Hospitals can buy medicines covered by government catalogs in bulk only after selection through government-run tenders.
All products are made at a single facility in Hainan. Production must meet continuing quality and legal requirements, and new medicines need approval from China’s National Medical Products Administration before sale. Some existing medicines are also subject to strict government price controls.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
China Pharma’s results hinge on Chinese hospital and pharmacy demand, especially for infection, respiratory and cardiovascular medicines, rather than the global biotechnology development cycle.
Universe Pharmaceuticals Inc. competes with China Pharma for medicine spending in China, with its cold-and-flu medicines overlapping China Pharma’s respiratory treatments. Sales of Universe’s Qiangli Pipa Syrup and children’s paracetamol granules offer a read on demand in that overlapping market.
China SXT and China Pharma both depend on Chinese hospital and pharmacy demand: China SXT sells processed traditional Chinese medicines, while China Pharma supplies manufactured pharmaceuticals through licensed distributors. China SXT’s sales of regular traditional Chinese medicine pieces to hospitals and drug stores offer a read on demand in those shared channels, rather than for China Pharma’s specific medicines.
No upcoming items to show.
Earnings, filings and other dated events show up here once their dates are set.
